Holly™
End-Stage Kidney Disease (ESKD)
Pre-clinical/Clinical DevelopmentActive
Key Facts
Indication
End-Stage Kidney Disease (ESKD)
Phase
Pre-clinical/Clinical Development
Status
Active
Company
About Nephrodite
Nephrodite is a private, pre-revenue biotech company developing Holly™, an investigational implantable dialysis system. The device has received FDA Breakthrough Device Designation, recognizing its potential to address a major unmet need in treating end-stage kidney disease. The company's mission is to move beyond 70-year-old dialysis technology by offering a portable, continuous hemofiltration solution that could significantly improve patient quality of life and reduce systemic healthcare costs. Founded in 2017 and led by a physician-founder, Nephrodite is positioned to disrupt the large but stagnant renal care market.
View full company profile